Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna Bologna Italy.
Department of General and Oncological Surgery Ospedale Mauriziano Umberto I Turin Italy.
BJS Open. 2018 Sep 3;3(2):186-194. doi: 10.1002/bjs5.100. eCollection 2019 Apr.
Markers of tumour biology may be valuable prognostic indicators after hepatic resection of colorectal cancer liver metastases (CRLMs). Identification of the aggressiveness of these metastases might inform the appropriateness of hepatic surgery.
Patients undergoing liver resection for CRLMs between January 2001 and July 2013 in four tertiary hospitals were reviewed. A mathematical model to estimate CRLM doubling times was constructed for patients with metachronous metastases. Tumour doubling time was investigated in relation to the features of colorectal cancer, including status. The hazard rate for recurrence and death following hepatectomy was explored through the Kernel-smoothed estimator.
Of 1063 patients undergoing liver resection for CRLMs, 361 with metachronous metastases undergoing single-stage hepatectomy were analysed. The mean doubling time in patients not receiving chemotherapy between surgery for colorectal cancer and CRLM was 71·4 days. Tumour doubling time was shorter in patients with more advanced primary tumour stages, with mutant and in those who did not receive chemotherapy. For fast-growing CRLMs (doubling time less than 48 days), the risk of recurrence was highest within the first postoperative year, and was about 7 per cent per month.
Primary features of colorectal cancer were linked to aggressiveness of CRLMs as measured by doubling time.
肿瘤生物学标志物可能是结直肠癌肝转移(CRLM)患者肝切除术后有价值的预后指标。这些转移灶侵袭性的确定可能有助于判断肝切除术的适宜性。
对 2001 年 1 月至 2013 年 7 月在 4 家三级医院接受 CRLM 肝切除术的患者进行了回顾性分析。为同期性转移患者构建了一种估计 CRLM 倍增时间的数学模型。研究了肿瘤倍增时间与结直肠癌特征(包括 KRAS 状态)之间的关系。通过核平滑估计器探讨了肝切除术后复发和死亡的危险率。
在 1063 例行 CRLM 肝切除术的患者中,分析了 361 例行同期肝切除术的同期性转移患者。在未接受结直肠癌和 CRLM 手术之间接受化疗的患者中,肿瘤的平均倍增时间为 71.4 天。肿瘤倍增时间在原发肿瘤分期较晚、KRAS 突变和未接受化疗的患者中较短。对于生长较快的 CRLM(倍增时间小于 48 天),术后第一年复发风险最高,约为每月 7%。
结直肠癌的原发特征与肿瘤倍增时间所反映的 CRLM 侵袭性有关。